Five Competitors Confirmed On Canadian Adalimumab
Amgen, Fresenius, Merck And Viatris Confirm Further Launches Of Humira Biosimilars
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
You may also be interested in...
Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.